Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder

被引:909
作者
Bymaster, FP [1 ]
Katner, JS [1 ]
Nelson, DL [1 ]
Hemrick-Luecke, SK [1 ]
Threlkeld, PG [1 ]
Heiligenstein, JH [1 ]
Morin, SM [1 ]
Gehlert, DR [1 ]
Perry, KW [1 ]
机构
[1] Lilly Res Labs, Lilly Corp Ctr, Neurosci Res Div, Indianapolis, IN 46285 USA
关键词
atomxetine; methylphenidate; reboxetine; Attention Deficit/Hyperactivity Disorder; norepinephrine; dopamine; microdialysis; Fos expression;
D O I
10.1016/S0893-133X(02)00346-9
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions. Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K-i) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters. In microdialysis studies, atomoxetine increased extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but did not alter 5-HTEX levels. Atomoxetine also increased DA(EX) concentrations in PFC 3-fold, but did not alter DA(EX) in striatum or nucleus accumbens. In contrast, the psychostimulant methylphenidate, which is used in ADHD therapy, increased NEEX and DA(EX) equally in PFC, but also increased DA(EX) in the striatum and nucleus accumbens to the same level. The expression of the neuronal activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration, but was not increased in the striatum or nucleus accumbens, consistent with the regional distribution of increased DA(EX). We hypothesize that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomoxetine in ADHD. In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities. (C) 2002 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.
引用
收藏
页码:699 / 711
页数:13
相关论文
共 89 条
[1]
[Anonymous], 2000, DIAGN STAT MAN MENT
[3]
Arnsten AFT, 1996, ARCH GEN PSYCHIAT, V53, P448
[4]
ASTONJONES G, 1991, PROG BRAIN RES, V88, P501
[5]
REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE-CHILDREN [J].
BARKLEY, RA .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 1977, 18 (02) :137-165
[6]
THE ADOLESCENT OUTCOME OF HYPERACTIVE-CHILDREN DIAGNOSED BY RESEARCH CRITERIA .1. AN 8-YEAR PROSPECTIVE FOLLOW-UP-STUDY [J].
BARKLEY, RA ;
FISCHER, M ;
EDELBROCK, CS ;
SMALLISH, L .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1990, 29 (04) :546-557
[7]
MOTOR ABILITIES AFTER FRONTAL LEUKOTOMY [J].
BENSON, DF ;
STUSS, DT .
NEUROLOGY, 1982, 32 (12) :1353-1357
[8]
NORADRENERGIC MODULATION OF COGNITIVE FUNCTION - CLINICAL IMPLICATIONS OF ANATOMICAL, ELECTROPHYSIOLOGICAL AND BEHAVIORAL-STUDIES IN ANIMAL-MODELS [J].
BERRIDGE, CW ;
ARNSTEN, AFT ;
FOOTE, SL .
PSYCHOLOGICAL MEDICINE, 1993, 23 (03) :557-564
[9]
Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder [J].
Biederman, J ;
Spencer, T .
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) :1234-1242
[10]
BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564